References
- NCCN Guidelines Version 7.2017. June 22, 2017. National Comprehensive Cancer Network, Inc; 2017. Available from: www.nccn.org
- Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology. 2014;25: 1681–1690.
- Zhang X, Ran Y. Prognostic role of elevated platelet count in patients with lung cancer: a systematic review and meta-analysis. International Journal of Clinical and Experimental Medicine. 2015;8(4): 5379–5387.
- Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A. Are neutro-phil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pacific Journal of Cancer Prevention. 2013;14(9): 5237–5242.
- Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917): 860–867.
- Hattar K, Franz K, Ludwig M, Sibelius U, Wilhelm J, Lohmeyer J, et al. Interactions between neutrophils and non-small cell lung cancer cells: enhancement of tumor proliferation and inflammatory mediator synthesis. Cancer Immunology, Immunotherapy, 2014;63(12): 1297–1306.
- Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nature Medicine. 2010;16(2): 219–223.
- Brambilla E, Le Teuff G, Marguet S, Lantuejoul S, Dunant A, Graziano S, et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. Journal of Clinical Oncology, 2016;34(11): 1223–1230.
- Oja AE, Piet B, van der Zwan D, Blaauwgeers H, Mensink M, de Kivit S, et al. Functional heterogeneity of CD4+ tumor-infiltrating lymphocytes with a resident memory phenotype in NSCLC. Frontiers in Immunology. 2018;9: 2654.
- Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 107(12): 2866–2872.
- Yu Y, Qian L, Cui J. Value of neutrophil to lymphocyte ratio for predicting lung cancer prognosis: a meta analysis of 7,219 patients. Molecular and Clinical Oncology. 2017;7(3): 498–506.
- Hua Z, Liuwei G, Bin Z, Lianmin Z, Changli W. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: a systematic review and meta-analysis. Scientific Report,. 2016;6: 22618.
- Zhao Q, Yuvan Z, Zhang H, Zhang X-P, Wang H-E, Wang Z-K, et al. Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: A meta-analysis including 3,720 patients. International Journal of Cancer. 2016;139(1): 164–170.
- Scilla K, Bentzen SM, Lam VK, Mohindra P, Nichols EM, Vythuis MA, et al. Neutrophil-lymphocyte ratio is a prognostic marker in patients with locally advanced (stage IIIA and IIIB) non-small cell lung cancer treated with combined modality therapy. The Oncologist. 2017;22(6): 737–742.
- Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, et al. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS ONE. 2018;13(2): e0193018.
- Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophillymphocyte ratio: experience in patients with cancer. Critical Reviews in Oncology/Hematology. 2013;88(1): 218–230.